Ruixia Z. Zhu

No. 155 North Nanjing Street
Shenyang, 110001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study.

Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study.

Journal: ImmunoTargets and therapy

Published: April 11, 2026

Development and Validation of a Nomogram to Predict Minimal Symptom Expression in AChR+ gMG Patients Undergoing Efgartigimod Therapy.

Development and Validation of a Nomogram to Predict Minimal Symptom Expression in AChR+ gMG Patients Undergoing Efgartigimod Therapy.

Journal: Current neuropharmacology

Published: March 20, 2026

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series.

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series.

Journal: Frontiers in immunology

Published: January 15, 2026

Exploring the metabolic mysteries: Mechanistic insights into lactylation-mediated regulation of autoimmune diseases.

Exploring the metabolic mysteries: Mechanistic insights into lactylation-mediated regulation of autoimmune diseases.

Journal: Autoimmunity reviews

Published: October 06, 2025

Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety.

Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety.

Journal: Current neuropharmacology

Published: October 05, 2025

Effectiveness and Safety of Eculizumab in Highly Active AChR+gMG and Its Therapeutic Response in Different Subtypes of gMG.

Effectiveness and Safety of Eculizumab in Highly Active AChR+gMG and Its Therapeutic Response in Different Subtypes of gMG.

Journal: ImmunoTargets and therapy

Published: September 09, 2025

Differential expression profiles of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple seronegative myasthenia gravis.

Differential expression profiles of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple seronegative myasthenia gravis.

Journal: Frontiers in immunology

Published: July 11, 2025

Mendelian randomization studies on ischemic stroke: a field synopsis and systematic review.

Mendelian randomization studies on ischemic stroke: a field synopsis and systematic review.

Journal: Journal of translational medicine

Published: May 28, 2025

Beyond the Surface: Investigating the Potential Mechanisms of Non-Motor Symptoms in Myasthenia Gravis.

Beyond the Surface: Investigating the Potential Mechanisms of Non-Motor Symptoms in Myasthenia Gravis.

Journal: European journal of neurology

Published: February 28, 2025

Telitacicept as a New Therapeutic Avenue for Generalized Myasthenia Gravis and Thymoma-Associated Myasthenia Gravis.

Telitacicept as a New Therapeutic Avenue for Generalized Myasthenia Gravis and Thymoma-Associated Myasthenia Gravis.

Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Published: February 16, 2025

Early Predictive Accuracy of Machine Learning for Hemorrhagic Transformation in Acute Ischemic Stroke: Systematic Review and Meta-Analysis.

Early Predictive Accuracy of Machine Learning for Hemorrhagic Transformation in Acute Ischemic Stroke: Systematic Review and Meta-Analysis.

Journal: Journal of medical Internet research

Published: January 23, 2025

Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports.

Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports.

Journal: Frontiers in immunology

Published: December 28, 2024

Showing 1-12 of 74

Last Updated: 09/26/2026